STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND CONJUGATES THEREOF
The invention relates to isolated Streptococcus pneumoniae serotype 15B capsular polysaccharide and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 15B capsular polysaccharide covalently linked to a carrier protein, processes for their preparation and immunogenic compositions comprising them.
1 .- 40 . (canceled)
41 . A process for the preparation of an immunogenic conjugate comprising Streptococcus pneumoniae serotype 15B capsular polysaccharide covalently linked to a carrier protein, the process comprising the steps of:
(a) compounding an activated polysaccharide with a carrier protein, wherein said activated polysaccharide is obtained by a process comprising the steps of reacting an isolated Streptococcus pneumoniae serotype 15B capsular polysaccharide comprising at least 0.6 mM acetate per mM of said serotype 15B capsular polysaccharide, with an oxidizing agent, wherein said activated polysaccharide has a molecular weight between about 100 and 300 kDa; and
(b) reacting the compounded, activated polysaccharide and carrier protein with a reducing agent to form a serotype 15B capsular polysaccharide-carrier protein conjugate.
42 . The process according to claim 41 wherein the carrier protein is CRM 197 .
43 . The process according to claim 41 wherein step (a) and step (b) are carried out in DMSO.
44 . The process according to claim 41 wherein step (a) and step (b) are carried out in aqueous solution.
45 . The process according to claim 41 wherein the concentration of activated serotype 15B capsular polysaccharide in step (b) is between 0.1 and 10 mg/mL, 0.5 and 5 mg/mL or 0.5 and 2 mg/mL.
46 . The process according to claim 41 wherein the concentration of activated serotype 15B capsular polysaccharide in step (b) is about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 or 3 mg/mL.
47 .- 50 . (canceled)
51 . The process according to claim 41 wherein the initial input ratio of activated serotype 15B capsular polysaccharide to carrier protein is between 5:1 and 0.1:1, 2:1 and 0.1:1, 2:1 and 1:1, 1.5:1 and 1:1, 0.1:1 and 1:1, 0.3:1 and 1:1, 0.6:1 and 1:1, or 0.6:1 and 1.5:1.
52 . The process according to claim 41 wherein the initial input ratio of activated serotype 15B capsular polysaccharide to carrier protein is about 0.4:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1 or 2:1.
53 .- 57 . (canceled)
58 . The process according to claim 41 wherein in step (b), the activated polysaccharide is reacted with between about 1 and 2 molar equivalent of sodium cyanoborohydride during about 40 to 50 hours at a temperature between about 20 to 26° C.
59 . The process according to claim 41 wherein said process comprises the additional following step:
(c) capping unreacted aldehyde by addition of NaBH 4 .
60 . The process according to claim 41 wherein said process further comprises the step of formulating the conjugate in a multivalent vaccine.
61 . The process according to claim 41 wherein the yield of the conjugation step (b) is greater than 50%.
62 . The process according to claim 41 wherein the yield of the conjugation step (b) is greater than 60%.
63 .- 80 . (canceled)
81 . The process according to claim 41 , wherein said oxidizing agent is periodate.
82 . The process according to claim 41 , wherein said oxidizing agent is sodium periodate.
83 . The process according to claim 41 , wherein said oxidizing agent is sodium metaperiodate.